Abiopharma

Technip Energies convenes its 2026 Annual General Meeting

Aurora Networks and HUBER+SUHNER Join Forces to Help Vodafone Germany Develop a Next-Generation Network

Register of shareholders, changes and capital position

Register of shareholders, changes and capital status – exercise of warrants

AIXCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Strategic Real Estate Industry Engagement, Long-Term Infrastructure Direction, and Industry Signals From the Evolving AI Stack

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved

Kulicke & Soffa Launches ASTERION™‑TW: Innovative Ultrasonic System Expands Power Assembly Portfolio